Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in VAL?
ValiRx Plc: THE INVESTMENT CASE

ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results

VAL201 is a treatment for metastatic prostate cancer and other solid tumours
ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results
INVESTMENT OVERVIEW: VAL The Big Picture
The market for prostate cancer treatments is a big one at US$8.2bn annually

ValiRx PLC (LON:VAL) chief executive Dr Satu Vainikka said the company was entering a “new and exciting phase” after being given the go-ahead by regulators to expand and accelerate its early-stage cancer study.

The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing the researchers to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.

It will do this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.

Effective dose

The change to the Phase I/II dose escalation study will also help ValiRx assess at what stage of the cancer’s progression VAL201 is most effective.

This in turn will allow the drug developer to plan “larger, outcome-oriented clinical trials”.

It will also help determine which route and with whom to take the project to its next stage. In other words, does it go-it-alone in the next phase, or partner with a company with deeper pockets?

Safe and well tolerated

The decision to accelerate the process follows on the back of data which showed VAL201 was extremely safe and well tolerated during the first stage of clinical development.

CEO Vainikka called the fast-track approval a “substantial breakthrough”.

“Since VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted, we anticipate that by increasing the dosage we will be able to see further anti-cancer activity,” she explained.

“This accelerated study will speed-up the human development of the compound and by doing so, it will save both time and money. 

“Most importantly, this potential treatment will more speedily meet the needs of those patients currently under-served by existing therapies.

“The pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena."  

Large potential market 

Certainly, the drug, if successful, has the blockbuster potential as it is tapping into a market worth US$8.2bn annually.

The latest success follows hard on the heels of a good news update last week from ValiRx on its other main compound, VAL401.

READ: ValiRx surges once again as top-line data from Phase II lung cancer trial impresses

In a Phase II lung cancer trial, the drug delivered a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment.

The company had previously reported back in September that 2mg doses of VAL401 were “broadly safe and tolerated”, while the treatment also demonstrated “suitability of our proposed treatment paradigm”.

More in the pipeline 

ValiRx is also developing VAL301, which is essentially a slight tweaking to VAL201 and is initially being developed to treat endometriosis.  It is currently in the late pre-clinical trial phase.

Its work to date shown that the drug has minimal impact on bone density or fertility, two common problems with standard treatments, and the plan is to get the necessary regulatory approvals to move 301 into the clinic next year.

In September, ValiRx said it would accelerate the pre-clinical trials of its VAL101 molecule after making a breakthrough with its development.

Based on ValiRx’s proprietary GeneICE platform, it works by switching off the gene that expresses Bcl-2 – a protein that is implicated in about half of all carcinoma cancers.

The first generation of the molecule was successful in reducing Bcl-2 and killing the cancer cells but it needed a few tweaks here and there to make it ready for commercial production.

WATCH: ValiSeek CEO on trial success

ValiRx went away and developed an optimised second generation, which has shown “improved technical efficacy and commercially viable efficient manufacturing” whilst still reducing Bcl-2.

The plan here is to get the pre-clinical studies completed and prepare for the compound’s entry into the clinic.

In today’s statement, boss Vainikka  said: “We are entering a new and very exciting phase, which should result in the crystallisation of substantial value.”

At 12.45pm, the shares were up 24% and changing hands for 6.83p each and have increased in value by 638% in the last month.

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
hepatitisC.jpg
Thu
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use